Procept BioRobotics Corp (NASDAQ: PRCT) on Tuesday, plunged -3.95% from the previous trading day, before settling in for the closing price of $50.83. Within the past 52 weeks, PRCT’s price has moved between $46.99 and $103.81.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 127.16% over the past five years. The company achieved an average annual earnings per share of 13.67%. With a float of $51.88 million, this company’s outstanding shares have now reached $54.72 million.
Let’s look at the performance matrix of the company that is accounted for 756 employees. In terms of profitability, gross margin is 60.5%, operating margin of -43.04%, and the pretax margin is -40.72%.
Procept BioRobotics Corp (PRCT) Insider Updates
Observing investor behavior towards Medical Devices industry stocks is more important than anything else. The insider ownership of Procept BioRobotics Corp is 5.37%, while institutional ownership is 92.19%. The most recent insider transaction that took place on Mar 18 ’25, was worth 312,404. In this transaction President, CEO of this company sold 5,475 shares at a rate of $57.06, taking the stock ownership to the 173,070 shares. Before that another transaction happened on Mar 18 ’25, when Company’s EVP, CFO sold 733 for $57.06, making the entire transaction worth $41,825. This insider now owns 107,991 shares in total.
Procept BioRobotics Corp (PRCT) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.4 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 13.67% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 37.06% during the next five years compared to -12.56% drop over the previous five years of trading.
Procept BioRobotics Corp (NASDAQ: PRCT) Trading Performance Indicators
Procept BioRobotics Corp (PRCT) is currently performing well based on its current performance indicators. A quick ratio of 8.01 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 11.92.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.76, a number that is poised to hit -0.49 in the next quarter and is forecasted to reach -0.96 in one year’s time.
Technical Analysis of Procept BioRobotics Corp (PRCT)
Procept BioRobotics Corp (NASDAQ: PRCT) saw its 5-day average volume 1.23 million, a positive change from its year-to-date volume of 0.96 million. As of the previous 9 days, the stock’s Stochastic %D was 13.86%. Additionally, its Average True Range was 3.78.
During the past 100 days, Procept BioRobotics Corp’s (PRCT) raw stochastic average was set at 3.31%, which indicates a significant decrease from 10.27% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 46.19% in the past 14 days, which was lower than the 50.32% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $62.92, while its 200-day Moving Average is $73.94. Nevertheless, the first resistance level for the watch stands at $52.31 in the near term. At $55.80, the stock is likely to face the second major resistance level. The third major resistance level sits at $57.89. If the price goes on to break the first support level at $46.73, it is likely to go to the next support level at $44.64. Assuming the price breaks the second support level, the third support level stands at $41.15.
Procept BioRobotics Corp (NASDAQ: PRCT) Key Stats
Market capitalization of the company is 2.68 billion based on 54,819K outstanding shares. Right now, sales total 224,500 K and income totals -91,410 K. The company made 68,240 K in profit during its latest quarter, and -18,860 K in sales during its previous quarter.
